These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 30799274)

  • 1. Modeling G2019S-LRRK2 Sporadic Parkinson's Disease in 3D Midbrain Organoids.
    Kim H; Park HJ; Choi H; Chang Y; Park H; Shin J; Kim J; Lengner CJ; Lee YK; Kim J
    Stem Cell Reports; 2019 Mar; 12(3):518-531. PubMed ID: 30799274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient-derived induced pluripotent stem cells.
    Son MY; Sim H; Son YS; Jung KB; Lee MO; Oh JH; Chung SK; Jung CR; Kim J
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):584-603. PubMed ID: 28235153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midbrain organoids mimic early embryonic neurodevelopment and recapitulate LRRK2-p.Gly2019Ser-associated gene expression.
    Zagare A; Barmpa K; Smajic S; Smits LM; Grzyb K; Grünewald A; Skupin A; Nickels SL; Schwamborn JC
    Am J Hum Genet; 2022 Feb; 109(2):311-327. PubMed ID: 35077669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.
    Vermilyea SC; Emborg ME
    Stem Cells Dev; 2018 Jul; 27(14):960-967. PubMed ID: 29402177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The multifaceted role of LRRK2 in Parkinson's disease: From human iPSC to organoids.
    Oun A; Sabogal-Guaqueta AM; Galuh S; Alexander A; Kortholt A; Dolga AM
    Neurobiol Dis; 2022 Oct; 173():105837. PubMed ID: 35963526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood.
    Matikainen-Ankney BA; Kezunovic N; Menard C; Flanigan ME; Zhong Y; Russo SJ; Benson DL; Huntley GW
    J Neurosci; 2018 Nov; 38(45):9700-9711. PubMed ID: 30249796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human iPSC-derived microglia carrying the LRRK2-G2019S mutation show a Parkinson's disease related transcriptional profile and function.
    Ohtonen S; Giudice L; Jäntti H; Fazaludeen MF; Shakirzyanova A; Gómez-Budia M; Välimäki NN; Niskanen J; Korvenlaita N; Fagerlund I; Koistinaho J; Amiry-Moghaddam M; Savchenko E; Roybon L; Lehtonen Š; Korhonen P; Malm T
    Sci Rep; 2023 Dec; 13(1):22118. PubMed ID: 38092815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mestre TA; Pont-Sunyer C; Kausar F; Visanji NP; Ghate T; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kasten M; Wadia PM; Zadikoff C; Kumar P; de Bie RM; Thomsen T; Lang AE; Schüle B; Klein C; Tolosa E; Marras C
    Mov Disord; 2018 Jul; 33(6):960-965. PubMed ID: 29665080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
    Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
    Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Models of LRRK2-Associated Parkinson's Disease.
    Xiong Y; Dawson TM; Dawson VL
    Adv Neurobiol; 2017; 14():163-191. PubMed ID: 28353284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2
    Juárez-Flores DL; González-Casacuberta I; Ezquerra M; Bañó M; Carmona-Pontaque F; Catalán-García M; Guitart-Mampel M; Rivero JJ; Tobias E; Milisenda JC; Tolosa E; Marti MJ; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G
    J Transl Med; 2018 Jun; 16(1):160. PubMed ID: 29884186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Targets from LRRK2 Rescue Phenotypes.
    Toh J; Chua LL; Ho P; Sandanaraj E; Tang C; Wang H; Tan EK
    Cells; 2021 Jan; 10(1):. PubMed ID: 33466414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling Parkinson's disease in midbrain-like organoids.
    Smits LM; Reinhardt L; Reinhardt P; Glatza M; Monzel AS; Stanslowsky N; Rosato-Siri MD; Zanon A; Antony PM; Bellmann J; Nicklas SM; Hemmer K; Qing X; Berger E; Kalmbach N; Ehrlich M; Bolognin S; Hicks AA; Wegner F; Sterneckert JL; Schwamborn JC
    NPJ Parkinsons Dis; 2019; 5():5. PubMed ID: 30963107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of an induced pluripotent stem cell line (CSC-41) from a Parkinson's disease patient carrying a p.G2019S mutation in the LRRK2 gene.
    Marote A; Pomeshchik Y; Collin A; Goldwurm S; Lamas NJ; Pinto L; Salgado AJ; Roybon L
    Stem Cell Res; 2018 Apr; 28():44-47. PubMed ID: 29414418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease.
    Rouaud T; Clairembault T; Coron E; Neunlist M; Anheim M; Derkinderen P
    Parkinsonism Relat Disord; 2017 Jul; 40():83-84. PubMed ID: 28483388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.